Drug Profile
Research programme: antibacterials - Cangene
Alternative Names: PEP 35Latest Information Update: 28 Feb 2014
Price :
$50
*
At a glance
- Originator Cangene Corporation
- Developer Emergent BioSolutions
- Class Antibodies; Monoclonal antibodies; Peptides
- Mechanism of Action Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Burkholderia infections; Postoperative infections
Most Recent Events
- 21 Feb 2014 Cangene Corporation has been acquired and merged into Emergent BioSolutions
- 18 Jul 2008 Preclinical development is ongoing
- 18 Jul 2008 Preclinical trials in Postoperative infections in USA (IV)